Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is less than 6 years of age~* Severe or moderately-severe hemophilia A as defined by a baseline factor VIII level \<= 2%, documented at screening or on the basis of historical data (e.g., at hemophilia diagnosis)~* Documented medical history of at least 50 exposure days for treatment with all other factor VIII products~* Subject's parent or legally authorized representative has provided informed consent~Exclusion Criteria:~* Detectable inhibitor to factor VIII measured in the screening sample by the local or central hemostasis laboratory~* History of inhibitor to factor VIII at any time prior to screening~* Subject has any one of the following laboratory abnormalities at the time of screening:~  1. platelet count \< 100,000/mm3~ 2. hemoglobin concentration \< 10 g/dL (100 g/L)~ 3. serum creatinine \> 1.5 times the ULN for age~ 4. total bilirubin \> 2 times the ULN for age~* Subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., platelet dysfunction secondary to uremia, liver failure, von Willebrand's Disease)~* Subject has known hypersensitivity to RECOMBINATE rAHF~* Subject is currently participating in another investigational drug study or has participated in any clinical study involving an investigational drug within 30 days of study entry~* Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).